Chronic kidney disease and cardiovascular therapeutics: time to close the evidence gaps.
作者信息
Chang Tara I, Chertow Glenn M
出版信息
J Am Coll Cardiol. 2011 Sep 6;58(11):1162-4. doi: 10.1016/j.jacc.2011.06.010.
Abstract
摘要
相似文献
1
Chronic kidney disease and cardiovascular therapeutics: time to close the evidence gaps.慢性肾脏病与心血管治疗：填补证据空白刻不容缓。
J Am Coll Cardiol. 2011 Sep 6;58(11):1162-4. doi: 10.1016/j.jacc.2011.06.010.
2
Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis.β受体阻滞剂在慢性肾脏病患者中的作用：系统评价和荟萃分析。
J Am Coll Cardiol. 2011 Sep 6;58(11):1152-61. doi: 10.1016/j.jacc.2011.04.041.
3
Systolic heart failure.
N Engl J Med. 2010 Apr 22;362(16):1545; author reply 1545-6. doi: 10.1056/NEJMc1002215.
4
Beta blockers in systolic heart failure.
Aust Fam Physician. 2008 Jun;37(6):391; author reply 391.
5
Clinical inquiry: what is the best beta-blocker for systolic heart failure?
J Fam Pract. 2015 Feb;64(2):122-3.
6
We should not hesitate to use beta-blockers for systolic heart failure with concomitant renal dysfunction.
Circ J. 2010 Aug;74(8):1526-7. doi: 10.1253/circj.cj-10-0585. Epub 2010 Jul 14.
7
Effect of Early Treatment With Ivabradine Plus Beta-blockers on Long-term Outcomes in Patients Hospitalized With Systolic Heart Failure.伊伐布雷定联合β受体阻滞剂早期治疗对收缩性心力衰竭住院患者长期预后的影响
Rev Esp Cardiol (Engl Ed). 2018 Dec;71(12):1086-1088. doi: 10.1016/j.rec.2017.12.006. Epub 2018 Jan 17.
8
Prescription Bias in the Treatment of Chronic Systolic Heart Failure.
Ann Intern Med. 2020 Jan 7;172(1):70-72. doi: 10.7326/M19-0476. Epub 2019 Oct 1.
9
Heart rate reduction is probably not the main beneficial mechanism by which beta blockade improves outcome in patients with systolic chronic heart failure.
Am J Cardiol. 2008 Aug 15;102(4):506-7. doi: 10.1016/j.amjcard.2008.05.043.
10
Beta-blockers for heart failure: why you should use them more.
J Fam Pract. 2011 Aug;60(8):472-7.
引用本文的文献
1
Beta-Blocker-Related Atrioventricular Conduction Disorders-A Single Tertiary Referral Center Experience.β受体阻滞剂相关的房室传导障碍：单中心三级转诊经验。
Medicina (Kaunas). 2022 Feb 20;58(2):320. doi: 10.3390/medicina58020320.
2
Comorbid Heart Failure and Renal Impairment: Epidemiology and Management.合并心力衰竭与肾功能损害：流行病学与管理
Cardiorenal Med. 2012 Dec;2(4):281-297. doi: 10.1159/000342487. Epub 2012 Oct 31.
3
Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature.血管紧张素转换酶抑制剂治疗肾功能障碍患者心力衰竭：文献回顾。
Heart Fail Rev. 2013 Mar;18(2):135-40. doi: 10.1007/s10741-011-9295-6.
本文引用的文献
1
Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis.β受体阻滞剂在慢性肾脏病患者中的作用：系统评价和荟萃分析。
J Am Coll Cardiol. 2011 Sep 6;58(11):1152-61. doi: 10.1016/j.jacc.2011.04.041.
2
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.辛伐他汀联合依折麦布降低慢性肾脏病患者 LDL 胆固醇的效果（心脏和肾脏保护研究）：一项随机安慰剂对照试验。
Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.
3
Kidney function and long-term medication adherence after myocardial infarction in the elderly.老年人心肌梗死后的肾功能与长期药物依从性。
Clin J Am Soc Nephrol. 2011 Apr;6(4):864-9. doi: 10.2215/CJN.07290810. Epub 2011 Jan 13.
4
Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.替米沙坦联合血管紧张素转换酶抑制剂对慢性心力衰竭血液透析患者死亡率和发病率的影响：一项双盲、安慰剂对照试验。
J Am Coll Cardiol. 2010 Nov 16;56(21):1701-8. doi: 10.1016/j.jacc.2010.03.105.
5
Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry.在慢性肾脏病患者中，基于证据的治疗方法在 ST 段抬高型心肌梗死和非 ST 段抬高型心肌梗死的短期结局中的应用：来自全国心血管数据急性冠状动脉治疗和干预结局网络注册的报告。
Circulation. 2010 Jan 26;121(3):357-65. doi: 10.1161/CIRCULATIONAHA.109.865352. Epub 2010 Jan 11.
6
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.蛋白尿、慢性肾病以及血管紧张素受体阻滞剂联合血管紧张素转换酶抑制剂对中重度心力衰竭患者的影响
Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.
7
Dividing stage 3 of chronic kidney disease (CKD): 3A and 3B.
Kidney Int. 2009 Aug;76(4):462-3; author reply 463-4. doi: 10.1038/ki.2009.178.
8
Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.荟萃分析：β受体阻滞剂剂量、心率降低与心力衰竭患者的死亡情况
Ann Intern Med. 2009 Jun 2;150(11):784-94. doi: 10.7326/0003-4819-150-11-200906020-00006.
9
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.瑞舒伐他汀与血液透析患者的心血管事件
N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30.
10
Associations of kidney function with cardiovascular medication use after myocardial infarction.心肌梗死后肾功能与心血管药物使用的关联。
Clin J Am Soc Nephrol. 2008 Sep;3(5):1415-22. doi: 10.2215/CJN.02010408. Epub 2008 Jul 9.
Zotero 插件